The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

NCT05018520 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

640

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Six Courses of R-CHOP Plus Two Courses of Rituximab
DRUG: Four Courses of R-CHOP Plus Four Courses of Rituximab

Sponsor

Ruijin Hospital